Antibodies News and Research

RSS

GenScript and Duke-NUS announce notice of allowance for “Surrogate Virus Neutralization Technology”

GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a world-leading life sciences research and application service and product provider, and Duke-NUS Medical School, a premier, research intensive medical school, announced today that the U.S. Patent and Trade Office has issued a notice of allowance for the patent application for a novel Surrogate Virus Neutralization Technology (sVNT).

23 Jun 2021

Ycharos announces publication of first characterization data and formation of industry advisory committee

YCharOS Inc., an open science company with the mission of characterizing commercially available antibody reagents for all human proteins, is pleased to announce the publication of its first characterization data and formation of its Industry Advisory Committee (IAC).

23 Jun 2021

Combination of SFRP2 and PD-1 immunotherapy halts aggressive metastatic cancer in preclinical model

In a cancer that has not seen new targeted therapies for over 20 years, MUSC Hollings Cancer Center researcher and oncologist Nancy Klauber-DeMore, M.D., is pioneering new discoveries.

22 Jun 2021

New antibody-drug conjugates also kill non-targeted neighboring tumor cells

How do you kill tumor cells that can't be targeted? Get their more susceptible neighbors to help.

22 Jun 2021

New universal vaccine protects mice against COVID-19 and other coronaviruses

Scientists at the University of North Carolina Gillings School of Global Public Health have developed a universal vaccine that protected mice not just against COVID-19 but also other coronaviruses and triggered the immune system to fight off a dangerous variant.

22 Jun 2021

Engineering nanobodies to fight against the SARS-CoV-2 virus

Scientists are pursuing a new strategy in the protracted fight against the SARS-CoV-2 virus by engineering nanobodies that can neutralize virus variants in two different ways.

22 Jun 2021

Do the Moderna and Pfizer COVID-19 vaccines elicit different antibody responses?

A recent study led by scientists from the United States has compared the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response among clinicians who have been immunized with Pfizer/BioNTech or Moderna coronavirus disease 2019 (COVID-19) vaccine.

22 Jun 2021

What is the optimal dosing regimen for remdesivir in COVID-19 patients? A computational model

A team of scientists from the Pennsylvania State University, USA, recently analyzed the pharmacodynamics and pharmacokinetics of antiviral drug remdesivir using computational models. Based on the study findings, which are yet to be peer-reviewed, the scientists recommend that for effective inhibition of SARS-CoV-2 infection, remdesivir should be used with other antiviral medicines, or its dosing regimen should be optimized to improve bioavailability.

22 Jun 2021

Is Rand Paul mixing up the vaccine message for Covid survivors?

Last week, Sen. Rand Paul (R-Ky.) posted a Twitter thread asserting that people who have survived a Covid-19 infection were unlikely to be reinfected and have better immunity against variants than those who have been vaccinated against — but not infected by — SARS-CoV-2, the virus that causes Covid.

22 Jun 2021

Use of nanotherapeutics in treating coronavirus diseases

Despite advancements in medicine, viral infections still pose a huge threat to human health and are a significant concern for global public health systems.

22 Jun 2021

Study: Immune responses may develop against other proteins produced by SARS-CoV-2

All coronaviruses produce four primary structural proteins and multiple nonstructural proteins. However, the majority of antibody-based SARS-CoV-2 research has focused on the spike and nucleocapsid proteins.

22 Jun 2021

Dual-antibody combination therapies effective against SARS-CoV-2 variants in animal study

COVID-19 therapies made from antibodies often are given to patients who are at high risk of severe illness and hospitalization. However, there have been nagging questions about whether such antibody therapies retain their effectiveness as worrisome new virus variants arise.

21 Jun 2021

Researchers uncover the role of macrophages in liver growth after massive resections

RUDN University doctors found out what role macrophages play in the recovery of the liver after the removal of its significant part. The results are published in the journal Biomedicine & Pharmacotherapy.

21 Jun 2021

Study shows a robust immune response to COVID-19 vaccine in breastfeeding health workers

A recent study by researchers from Poland, published in the journal Vaccines, shows how levels of IgA and IgG antibodies specific to the spike glycoprotein of SARS-CoV-2 increase in both breast milk and serum samples of mothers following vaccination against COVID-19 – with important implications for further vaccine planning endeavors.

21 Jun 2021

Multivalent antibodies show high potency against SARS-CoV-2 in new study

A new study in the journal Nature Communications describes the process of converting a SARS-CoV-2 antibody into a multivalent form, thus enabling it to bind at various different points with its epitope.

21 Jun 2021

A World First: sequencing polyclonal antibodies using only proteomics

News-Medical speaks to Bin Ma, President of Rapid Novor, about their latest research that sequenced polyclonal antibodies using only proteomics.

From Rapid Novor Inc 21 Jun 2021

COVID-19 studies should provide sex-disaggregated data, researchers warn

Researchers have warned that studies examining sex-specific responses to infection with SARS-CoV-2 must provide sex-disaggregated data.

21 Jun 2021

Study shows that COVID-19 was present in five U.S. states in December 2019, even before the first reported case in China

In a recent study, a group of researchers aimed to identify exactly how early SARS-CoV-2 was circulating throughout the United States.

21 Jun 2021

Can convalescent plasma therapy improve COVID-19 outcomes in patients with hematologic cancers?

A recent study discusses the findings of a study on patients with hematologic cancers who received convalescent plasma therapy following their diagnosis of COVID-19.

21 Jun 2021

Blocking IL-11 signaling can promote liver regeneration after paracetamol-induced damage

Scientists at Duke-NUS Medical School and National Heart Centre Singapore, in collaboration with colleagues in Singapore and the UK, have shown that the human form of the signaling protein interleukin 11 (IL-11) has a damaging effect on human liver cells--overturning a prior hypothesis that it could help livers damaged by paracetamol poisoning.

18 Jun 2021

Antibodies News and Research

GenScript and Duke-NUS announce notice of allowance for “Surrogate Virus Neutralization Technology”

Ycharos announces publication of first characterization data and formation of industry advisory committee

Combination of SFRP2 and PD-1 immunotherapy halts aggressive metastatic cancer in preclinical model

New antibody-drug conjugates also kill non-targeted neighboring tumor cells

New universal vaccine protects mice against COVID-19 and other coronaviruses

Engineering nanobodies to fight against the SARS-CoV-2 virus

Do the Moderna and Pfizer COVID-19 vaccines elicit different antibody responses?

What is the optimal dosing regimen for remdesivir in COVID-19 patients? A computational model

Is Rand Paul mixing up the vaccine message for Covid survivors?

Use of nanotherapeutics in treating coronavirus diseases

Study: Immune responses may develop against other proteins produced by SARS-CoV-2

Dual-antibody combination therapies effective against SARS-CoV-2 variants in animal study

Researchers uncover the role of macrophages in liver growth after massive resections

Study shows a robust immune response to COVID-19 vaccine in breastfeeding health workers

Multivalent antibodies show high potency against SARS-CoV-2 in new study

A World First: sequencing polyclonal antibodies using only proteomics

COVID-19 studies should provide sex-disaggregated data, researchers warn

Study shows that COVID-19 was present in five U.S. states in December 2019, even before the first reported case in China

Can convalescent plasma therapy improve COVID-19 outcomes in patients with hematologic cancers?

Blocking IL-11 signaling can promote liver regeneration after paracetamol-induced damage

Antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo